MONARCHER: A PHASE 2, RANDOMIZED, MULTICENTER, 3-ARM, OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS TRASTUZUMAB WITH OR WITHOUT FULVESTRANT TO STANDARD-OF-CARE CHEMOTHERAPY OF PHYSICIAN'S CHOICE PLUS TRASTUZUMAB IN WOMEN WITH HR+, HER2+ LOCALLY ADVANCED OR METASTATIC BREAST CANCER.

Registry ID

I3Y-MC-JPBZ

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

ELI LILLY CANADA INC

Start date

2016-09-14

Last update

2016-03-30

Conditions

• BREAST CANCER METASTATIC
• BREAST CANCER HER2-POSITIVE

Related clinical trials

• A TWO-PART, SEAMLESS, MULTICENTER, RANDOMIZED, OPEN-LABEL, ADAPTIVE PHASE II/III STUDY OF THE BLOOD-BRAIN BARRIER PENETRANT RO7771950 VERSUS TUCATINIB, BOTH IN COMBINATION WITH TRASTUZUMAB AND CAPECITABINE, IN PATIENTS WITH PRETREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER, WITH OR WITHOUT CENTRAL NERVOUS SYSTEM METASTASES
• HERTHENA-BREAST-01: A PHASE 1B/2, MULTICENTER, OPEN-LABEL, DOSE FINDING STUDY TO EVALUATE THE SAFETY AND ANTITUMOR ACTIVITY OF PATRITUMAB DERUXTECAN IN PARTICIPANTS WITH HER2 POSITIVE UNRESECTABLE LOCALLY ADVANCED BREAST CANCER OR METASTATIC BREAST CANCER
• A RANDOMIZED, OPEN-LABEL STUDY COMPARING THE BRIA-IMT REGIMEN IN COMBINATION WITH CHECK POINT INHIBITOR VS PHYSICIAN'S CHOICE IN METASTATIC BREAST CANCER
• A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ZANIDATAMAB IN COMBINATION WITH PHYSICIAN¿S CHOICE CHEMOTHERAPY COMPARED TO TRASTUZUMAB IN COMBINATION WITH PHYSICIAN'S CHOICE CHEMOTHERAPY FOR THE TREATMENT OF PARTICIPANTS WITH METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE PROGRESSED ON, OR ARE INTOLERANT TO, PREVIOUS TRASTUZUMAB DERUXTECAN TREATMENT
• A PHASE 1B/2 OPEN-LABEL STUDY OF DISITAMAB VEDOTIN MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS
• A PHASE 3, RANDOMIZED, MULTI-CENTER, OPEN-LABEL STUDY OF DB-1303 VERSUS INVESTIGATOR¿S CHOICE CHEMOTHERAPY IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-LOW, HORMONE RECEPTOR POSITIVE (HR+) METASTATIC BREAST CANCER PATIENTS WHOSE DISEASE HAS PROGRESSED ON ENDOCRINE THERAPY (ET) (DYNASTY-BREAST02)

View on source registry